EUVIMEDEUVIMED entdecken
Crossref

Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration

Hidetaka Matsumoto, Junki Hoshino, Saki Numaga, Yosuke Asatori, Hideo Akiyama

Japanese Journal of Ophthalmology · 2025

DOI: 10.1007/s10384-025-01229-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Hidetaka Matsumoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. hide-m@gunma-u.ac.j…. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD). STUDY DESIGN: Retrospective, interventional case series. METHODS: We retrospectively analyzed 83 consecutive eyes of 80 patients with treatment-naïve nAMD who received 3 monthly injections of aflibercept 8 mg as a loading phase treatment. Best-corrected visual acuity (BCVA), foveal thickness, central choroidal thickness (CCT), and dry macula achievement were all assessed every 4 weeks. Moreover, polypoidal lesion regression was evaluated after the loading phase. RESULTS: Seventy eyes (84.3%) of 67 patients completed the 3 monthly injections of aflibercept 8 mg. In these cases, BCVA was 0.33±0.45 at baseline and showed significant improvement to 0.22±0.38 at week 12 (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorVisual AcuityWet Macular DegenerationHumansIntravitreal InjectionsRetrospective StudiesMaleFemaleTomography, Optical CoherenceFluorescein AngiographyAgedTreatment OutcomeFollow-Up StudiesAged, 80 and overFundus OculiAngiogenesis InhibitorsDose-Response Relationship, DrugMiddle AgedVascular Endothelial Growth Factor AChoroidMacula Lutea

Stichwörter der Autor:innen

Aflibercept 8 mgAge-related macular degenerationAnti-VEGFLoading phase treatment

Substanzen

afliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. hide-m@gunma-u.ac.jp.
  • Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.

Zitieren

APA

Matsumoto, H., Hoshino, J., Numaga, S., Asatori, Y., & Akiyama, H. (2025). Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-025-01229-9

Vancouver

Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-025-01229-9

BibTeX
@article{Matsumoto2025,
  author = {Matsumoto, Hidetaka and Hoshino, Junki and Numaga, Saki and Asatori, Yosuke and Akiyama, Hideo},
  title = {Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration},
  journal = {Japanese Journal of Ophthalmology},
  year = {2025},
  doi = {10.1007/s10384-025-01229-9}
}
Kostenlos starten →